ENALAPRILAT

Post-LOE

enalaprilat

Pfizer

ANDAINJECTIONINJECTABLE

Approved

Aug 2000

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

ENALAPRILAT (enalaprilat) by Pfizer is mechanism of action intravenous enalaprilat, or oral enalapril, after hydrolysis to enalaprilat, inhibits ace in human subjects and animals. Approved for hypertension. First approved in 2000.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

Mechanism of Action Intravenous enalaprilat, or oral enalapril, after hydrolysis to enalaprilat, inhibits ACE in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates…

Indications (1)

hypertension

Worked on ENALAPRILAT at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.